Industry: Pharmaceuticals | NYSE
Organon & Co is not compliant with Shariah. The company’s financials fail all the five standards we check against.
|Market cap: 9,316 M||Rev. Growth: 103.62%|
|Debt/36 mo MC||110.41%||✗|
|Cash/36 mo MC||8.91%||✓|
|AR/36 mo MC||16.79%||✓|
|Debt/24 mo MC||110.41%||✗|
|Cash/24 mo MC||8.91%||✓|
|AR/24 mo MC||16.79%||✓|
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Total Analysts: 7
Organon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates approximately six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
To understand how the screening is done, please read the Shariah Screening Methodology page.